ArticleBMC infectious diseases2025
A retrospective analysis of the correlation between the glucose-to-albumin ratio and 28-day mortality in sepsis patients.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Preoperative Glucose-Albumin Ratio and Its Association with Postoperative Outcomes in Critically Ill Adult Burn Patients: A Retrospective Cohort Study of 1119 Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic Significance of the Prothrombin Time-International Normalized Ratio to Albumin Ratio in Cancer Patients with Complication of Sepsis: A Retrospectively Cohort Study.Shock (Augusta, Ga.) · 2026Article
- Article
- Glucose-to-albumin ratio predicts short-term mortality in critically ill patients with acute pancreatitis.Scientific reports · 2026Article
- A simple ratio, a complex outcome: glucose-to-albumin ratio predicts delirium in ICU patients after cardiac surgery.BMC cardiovascular disorders · 2025Article
- Risk factors for mortality and development of a predictive model in pediatric sepsis.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Glucose to Albumin Ratio (GAR) is considered a novel biomarker for predicting the risk of mortality following intracerebral hemorrhage. Despite the absence of existing research examining the association between the GAR and mortality in sepsis, this study is designed to delineate the relationship between the GAR and the risk of all-cause mortality within a 28-day period in patients diagnosed with sepsis.
methodsThis study is a retrospective cohort study, primarily based on data from the Medical Information Mart for Intensive Care (MIMIC, version 2.2). This study targeted the circumstances of adult sepsis patients admitted to intensive care units. The primary investigation was centered on the correlation between the GAR and the mortality from all causes within a 28-day period post-admission for sepsis.
resultsThis study included a total of 6731 patients with sepsis, with an all-cause mortality rate of 24.7% within 28 days after admission. Multivariate Cox regression analysis showed that, after adjusting for all confounding factors, the GAR is an independent risk factor for 28-day all-cause mortality in sepsis patients (HR:1.11, 95% CI: 1.04-1.19). Curve fitting revealed a J-shaped relationship between GAR and 28-day mortality rates in sepsis patients, and further analysis of the inflection point showed a critical value of GAR at 27.93. Finally, subgroup analysis indicated no interaction effect of GAR across different subgroups (P > 0.05).
conclusionThe GAR is significantly correlated with the all-cause mortality rate within 28 days for patients with sepsis, a finding that holds substantial clinical significance. Therefore, prospective studies are needed in the future to further validate this relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.